Ms. Gregory is an executive vice president and chief financial officer at ContraFect Corporation. ContraFect, a New York-based biotechnology company, is committed to developing technologies, treatments, and products that will target and kill the most virulent and resistant microorganisms—including gram-positive bacteria, such as Staphylococcus (MRSA), and viruses, such as Influenza.
Prior to ContraFect, Ms. Gregory held several executive management positions at Five Prime Therapeutics and Lexicon Pharmaceuticals.
Ms. Gregory has been actively involved in a variety of public and private financings, including a private equity agreement designed to provide financing of up to $550 million for Lexicon and Lexicon's $220 million initial public offering.
While at FivePrime and Lexicon, she led transactions for several strategic partnerships including those with GlaxoSmithKline, Human Genome Sciences, Genentech, Inc., Bristol-Myers Squibb Company and Takeda Pharmaceutical Company Limited. In addition, she led the negotiations for Lexicon's acquisition of the chemistry company that provided the foundation for Lexicon's novel drug programs.
Additionally, Ms. Gregory served as an investment banker where she was head of investment banking for Punk, Ziegel & Company, a specialty technology and healthcare investment banking firm and was an investment banker with Dillon, Read & Co., Inc. She currently serves as a Director on the board of Clinipace on behalf of and as Special Advisor to Morgan Stanley Expansion Capital and on the board of The Global TB Alliance for Drug Development, primarily funded by the Gates Foundation.
Ms. Gregory received her B.A. from George Washington University's Elliott School of International Affairs where she was elected to Phi Beta Kappa and her M.B.A. from the Wharton School of the University of Pennsylvania.